Eko Health developed an AI algorithm that, combined with noninvasive heart tests, may be able to accurately identify pulmonary hypertension.

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Inhibiting GLS1 reduced high blood pressure in the right side of the heart of PAH rats and improved various measures of heart ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the ...

Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.

Published in the Journal of the American Heart Association, the study showcases the potential of AI-powered heart sound ...

Eko Health has been advancing the use of artificial intelligence to help providers detect the early signs of disease, ...

Seropositive rheumatoid arthritis may be protective against the development of PAH, based on results of Mendelian randomization analyses.

Gossamer Bio Inc. has released new data showing its inhaled kinase inhibitor, seralutinib, has long-lasting effects on ...

If you're concerned about your blood pressure, be sure to talk to your doctor. The force of blood that pushes against artery walls every time the heart beats. Blood pressure is often measured ...

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.